#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15702	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2397	802.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1824	1824	T	971	T,C,G,A	968,1,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15702	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2397	802.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1558	1558	C	999	C,A,T	996,2,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26230	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3952	826.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1883	1883	A	1032	A	1032	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26230	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3952	826.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2517	2517	C	909	C,A	908,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26230	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3952	826.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2591	2591	A	816	A,C	815,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26230	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3952	826.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3143	3143	C	928	C,A,G	925,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_G_01367c	folP.WHO_G_01367c	1	1	27	2172	folP	852	852	100.0	folP.l15.c4.ctg.1	2097	129.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1316	1318	AGC	219;219;221	A,G;G,A;C	218,1;217,2;221	folP.WHO_G_01367c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6040	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3967	189.8	1	SNP	p	S91F	0	.	.	271	273	TCC	859	861	TCC	234;234;229	T;C;C,A	234;234;228,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6040	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3967	189.8	1	SNP	p	D95G	0	.	.	283	285	GAC	871	873	GAC	230;233;233	G;A;C,T	230;233;232,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6040	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3967	189.8	1	SNP	p	D95N	0	.	.	283	285	GAC	871	873	GAC	230;233;233	G;A;C,T	230;233;232,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1816	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1776	127.4	0	.	p	.	0	A39T	NONSYN	115	117	GCC	654	656	ACC	161;162;160	A;C;C	161;162;160	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1816	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1776	127.4	0	.	p	.	0	R44H	NONSYN	130	132	CGC	669	671	CAC	165;165;168	C;A;C	165;165;168	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1816	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1776	127.4	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	852	854	CAC	272;271;273	C;A,C;C	272;270,1;273	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1816	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1776	127.4	1	SNP	p	G45D	0	.	.	133	135	GGC	672	674	GGC	170;171;170	G;G;C	170;171;170	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1132	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1348	104.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	6300	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3400	231.0	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1854	1856	GCA	288;291;289	G,T;C;A	287,1;291;289	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	6300	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3400	231.0	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2337	2339	ATT	286;286;286	A;T;T	286;286;286	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	6300	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3400	231.0	1	SNP	p	D86N	0	.	.	256	258	GAC	807	809	GAC	294;294;296	G;A,C;C,G,A	294;293,1;294,1,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	6300	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3400	231.0	1	SNP	p	S87R	0	.	.	259	261	AGT	810	812	AGT	291;292;293	A,C,G;G;T,G	288,2,1;292;291,2	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	6300	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3400	231.0	1	SNP	p	S87I	0	.	.	259	261	AGT	810	812	AGT	291;292;293	A,C,G;G;T,G	288,2,1;292;291,2	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	6300	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3400	231.0	1	SNP	p	S87W	0	.	.	259	261	AGT	810	812	AGT	291;292;293	A,C,G;G;T,G	288,2,1;292;291,2	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	6300	parC	2304	2304	99.74	parC.l6.c4.ctg.1	3400	231.0	1	SNP	p	S88P	0	.	.	262	264	TCC	813	815	TCC	293;294;293	T,G,A;C;C,A	291,1,1;294;292,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4086	parE	1986	1986	99.9	parE.l6.c4.ctg.1	3104	164.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1768	1770	GGC	217;212;212	G;G;C	217;212;212	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.15.001	penA.15.001	1	1	27	4004	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2853	174.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1457	1459	GCA	260;259;265	G,T;C,A;A	259,1;258,1;265	penA.15.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4004	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2853	174.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1460	1462	ATC	267;269;272	A;T;C	267;269;272	penA.15.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4004	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2853	174.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1472	1474	GTG	255;258;258	G;T,G,C;G	255;256,1,1;258	penA.15.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4004	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2853	174.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1472	1474	GTG	255;258;258	G;T,G,C;G	255;256,1,1;258	penA.15.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4004	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2853	174.9	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1973	1975	ACC	232;234;232	A;C,G;C	232;233,1;232	penA.15.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4004	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2853	174.9	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2027	2029	GCG	220;220;220	G,T;C,A;G,C	219,1;219,1;219,1	penA.15.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4004	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2853	174.9	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2027	2029	GCG	220;220;220	G,T;C,A;G,C	219,1;219,1;219,1	penA.15.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4004	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2853	174.9	1	SNP	p	G542S	0	.	.	1624	1626	GGC	2150	2152	GGC	229;229;228	G;G,C;C,T	229;228,1;227,1	penA.15.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4004	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2853	174.9	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2159	2161	GGC	215;215;213	G;G;C,G	215;215;212,1	penA.15.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4004	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2853	174.9	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2177	2179	CCG	208;211;212	C;C;G,C	208;211;211,1	penA.15.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6490	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3508	230.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2542	porA	1146	1146	99.65	porA.l15.c17.ctg.1	2183	145.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	749	749	C	201	C,T	200,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	378	porB1a	984	330	90.12	porB1a.l6.c30.ctg.1	1441	29.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	792	794	AAT	5;4;4	A;A;T	5;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	378	porB1a	984	330	90.12	porB1a.l6.c30.ctg.1	1441	29.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	795	797	AAT	4;4;4	A;A;T	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	378	porB1a	984	330	90.12	porB1a.l6.c30.ctg.1	1441	29.0	0	.	p	.	0	A222V	NONSYN	664	666	GCT	807	809	GTT	4;4;4	G;T;T	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	378	porB1a	984	330	90.12	porB1a.l6.c30.ctg.1	1441	29.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	819	821	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	378	porB1a	984	330	90.12	porB1a.l6.c30.ctg.1	1441	29.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	842	844	GTA	1;1;1	G;T;A	1;1;1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	378	porB1a	984	330	90.12	porB1a.l6.c30.ctg.1	1441	29.0	0	.	p	.	0	D238fs	FSHIFT	712	712	G	854	854	G	3	G	3	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3034	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1653	224.7	0	.	p	.	0	G46D	NONSYN	136	138	GGC	488	490	GAC	248;249;253	G;A;C	248;249;253	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3034	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1653	224.7	0	.	p	.	0	E48G	NONSYN	142	144	GAA	494	496	GGA	251;255;258	G;G,A;A	251;254,1;258	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3034	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1653	224.7	0	.	p	.	0	F135L	NONSYN	403	405	TTT	755	757	CTT	263;266;264	C;T;T	263;266;264	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3034	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1653	224.7	0	.	p	.	0	R143G	NONSYN	427	429	AGA	779	781	GGA	273;270;272	G;G,A;A	272;269,1;272	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3034	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1653	224.7	0	.	p	.	0	G189S	NONSYN	565	567	GGC	917	919	AGC	269;265;263	A,G;G,T;C	268,1;264,1;263	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3034	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1653	224.7	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	983	983	T	270	T	270	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3034	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1653	224.7	1	SNP	p	G120K	0	.	.	358	360	GGT	710	712	GGT	276;274;273	G;G,T;T,G	276;272,2;272,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3034	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1653	224.7	1	SNP	p	A121N	0	.	.	361	363	GCC	713	715	GCC	273;274;273	G,T,A;C;C	271,1,1;274;273	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	3034	porB1b	1035	1035	96.1	porB1b.l15.c17.ctg.1	1653	224.7	1	SNP	p	A121D	0	.	.	361	363	GCC	713	715	GCC	273;274;273	G,T,A;C;C	271,1,1;274;273	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10690	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5428	245.6	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2312	2314	CAT	301;301;303	C;A,C;T,A	301;300,1;302,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1578	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1455	135.3	1	SNP	p	V57M	0	.	.	169	171	GTG	760	762	GTG	283;286;286	G;T;G	283;286;286	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
